FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

8 letters match. Newest first.

  1. Aytu Biopharma

    FDA says Aytu Biopharma’s sponsored links for ADHD drug Cotempla XR-ODT are false or misleading and misbrand it.

    High risk
  2. Aytu Biopharma

    FDA warned Aytu Biopharma that sponsored links for ADHD drug Adzenys XR-ODT are false or misleading because they omit risk information.

    High risk
  3. Eli Lilly and Company

    FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.

    High risk
  4. Eli Lilly and Company

    FDA says Eli Lilly's Zepbound online video omitted risk and limitations information and was not submitted to FDA.

    High risk
  5. Eli Lilly and Company

    FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.

    Low
  6. Sprout Pharmaceuticals, Inc.

    FDA warned Sprout Pharmaceuticals that a CEO Instagram post for Addyi omitted risks and indication limits.

    High risk
  7. Sarfez Pharmaceuticals, Inc.

    FDA says Sarfez made false or misleading efficacy and risk claims for Soaanz (torsemide) in webpages, pamphlet, and exhibit panel.

    High risk
  8. CooperSurgical, Inc.

    FDA says CooperSurgical’s Paragard video omitted all risk information, making the birth-control promotion misleading and misbranded.

    Low